West Virginia Medicaid

Does West Virginia Medicaid cover Wegovy?

Quick answer · Weight Loss

West Virginia Medicaid does not cover it for weight loss on Medicaid.

  • Medicaid: Not covered. Agents used for the purpose of weight loss are typically a benefit exclusion. Coverage of Wegovy will only be considered for the secondary prevention of a cardiovascular event and/or a diagnosis of MASH.

Last verified June 3, 2026. Policy effective January 1, 2026. Source: download. How we verify this data →

Check your card for your exact plan →

Wegovy for Weight Loss

What West Virginia Medicaid requires, by plan type. Open this indication on its own page →

Medicaid

Not covered

Agents used for the purpose of weight loss are typically a benefit exclusion. Coverage of Wegovy will only be considered for the secondary prevention of a cardiovascular event and/or a diagnosis of MASH.

Policy note: Weight loss as a standalone indication is explicitly excluded. Coverage of Wegovy is only considered for CV risk reduction (secondary prevention) and/or MASH.

Policy effective January 1, 2026 · verified June 3, 2026 · source: download

Wegovy for Heart Disease Risk Reduction

What West Virginia Medicaid requires, by plan type. Open this indication on its own page →

Medicaid

Covered with requirements

What you need to qualify

  • BMI of 27 or higher
  • A1C no higher than 6.5%
  • Prescribed by or in consultation with a specialist
  • Established cardiovascular disease (MI, stroke, and PAD)
  • Lab results confirming eligibility
  • Not being used to treat type 1 diabetes

Qualification pathways

You can qualify through any one of these.

CV Risk Reduction — Initial Approval

All of:

  • Patient is within the FDA-label recommended age range
  • BMI >= 27 kg/m2 (date and results of most recent BMI calculation stated on request)
  • Prescribed by or in consultation with an M.D./D.O. or specialty trained prescriber with clinical specialty certification/degree in cardiology, vascular surgery, or neurology
  • Patient attests to behavioral modification including a reduced calorie diet and increased physical activity
  • HbA1c level taken within the last 6 months is provided
  • HbA1c <= 6.5%
  • Patient does NOT have type 1 or type 2 diabetes
  • Medication will not be used with other GLP-1 agonist agents

Plus any one of:

  • Prior myocardial infarction
  • Prior stroke
  • Symptomatic peripheral arterial disease (PAD) demonstrated by: formal vascular laboratory testing showing intermittent claudication with ABI <= 0.85 at rest, OR peripheral revascularization procedure, OR amputation due to atherosclerotic disease

Documentation to bring

  • Documentation of BMI >= 27 kg/m2 with date and results of most recent BMI calculation
  • Prescription by or documentation of consultation with M.D./D.O. or specialist in cardiology, vascular surgery, or neurology
  • Documentation of qualifying CV event: prior MI, prior stroke, or symptomatic PAD (with supporting vascular lab results showing ABI <= 0.85, or evidence of peripheral revascularization or amputation due to atherosclerotic disease)
  • Patient attestation of behavioral modification including reduced calorie diet and increased physical activity
  • HbA1c lab result taken within the last 6 months
  • Confirmation that patient does not have type 1 or type 2 diabetes and HbA1c is <= 6.5%
  • Confirmation that medication will not be co-administered with other GLP-1 agonist agents

Approval and renewal

  • Initial approval: 3 months
  • Renewal: every 6 months
  • To renew, the plan looks for Patient continues to meet all initial approval criteria AND demonstrates continued documented compliance AND is taking an appropriate maintenance dose of 1.7 mg or 2.4 mg per week. If 1.7 mg dose is intolerable, medication should be discontinued. Initial approval criteria (including T2DM/T1DM exclusion and A1C <= 6.5%) are re-verified at continuation and staying on a maintenance dose of at least 1.7 mg.

Not covered when

  • Type 2 diabetes (excluded — HbA1c must be <= 6.5% and no T1DM or T2DM diagnosis)
  • Concomitant use with other GLP-1 agonist agents
  • Type 1 diabetes

Policy note: HbA1c > 6.5% is an exclusion criterion. Both type 1 and type 2 diabetes are explicitly excluded. Symptomatic PAD must be demonstrated by one of three specified methods: ABI <= 0.85 on formal vascular lab testing, peripheral revascularization procedure, or amputation due to atherosclerotic disease. Initial approval is 90 days; continuation approvals are 6 months. Prescriber must be an M.D./D.O. or specialty-certified in cardiology, vascular surgery, or neurology.

Policy effective January 1, 2026 · verified June 3, 2026 · source: download

Wegovy for Liver Disease (MASH)

What West Virginia Medicaid requires, by plan type. Open this indication on its own page →

Medicaid

Covered with requirements

What you need to qualify

  • 12 months of a documented diet and exercise program
  • Prescribed by or in consultation with a specialist
  • Confirmed MASH diagnosis by liver_biopsy, FibroScan_VCTE, and MRE, fibrosis stage F2 to F3

Qualification pathways

You can qualify through any one of these.

MASH — Initial Approval

All of:

  • Patient has a diagnosis of noncirrhotic MASH with moderate to advanced liver fibrosis (stage F2 or F3)
  • Patient is within the FDA-label recommended age range
  • Prescribed by or in consultation with an M.D./D.O. or specialty trained prescriber with clinical specialty certification/degree in gastroenterology or hepatology
  • Medication will be used in combination with appropriate diet and exercise therapy; documentation of diet, exercise, and weight loss counseling/treatment provided within the past 12 months must be submitted
  • Patient is compliant on stable dosages of medications for diabetes, dyslipidemia, and hypertension (where applicable)
  • For patients with both T2DM and MASH, diabetes therapy must be managed with a GLP-1 receptor agonist approved for that indication at the appropriate dose (per WV Preferred Drug List)
  • Medication will not be used with other GLP-1 agonist agents

Plus any one of:

  • Liver biopsy within the past 1 year showing NAFLD activity score >= 4 with score > 1 in ALL of: Steatosis, Ballooning, and Lobular inflammation
  • Liver stiffness measurement by vibration-controlled transient elastography (e.g., FibroScan) or magnetic resonance elastography (MRE)

Documentation to bring

  • Diagnosis documentation of noncirrhotic MASH with moderate to advanced liver fibrosis (stage F2 or F3)
  • Liver biopsy results within the past 1 year showing NAFLD activity score >= 4 with score > 1 in steatosis, ballooning, and lobular inflammation; OR liver stiffness measurement by FibroScan (VCTE) or MRE confirming stage F2 or F3 fibrosis
  • Prescription by or documentation of consultation with M.D./D.O. or specialist in gastroenterology or hepatology
  • Documentation of diet, exercise, and weight loss counseling/treatment provided within the past 12 months
  • Documentation of compliance with stable dosages of medications for diabetes, dyslipidemia, and hypertension (where applicable)
  • For patients with both T2DM and MASH: documentation that diabetes is managed with a GLP-1 receptor agonist approved for that indication per WV Preferred Drug List
  • Confirmation that medication will not be co-administered with other GLP-1 agonist agents

Approval and renewal

  • Initial approval: 3 months
  • Renewal: every 12 months
  • To renew, the plan looks for Patient continues to meet all initial approval criteria AND demonstrates continued documented compliance AND has not progressed to stage F4 (cirrhosis) AND demonstrates positive clinical response (resolution of steatohepatitis and no worsening of liver fibrosis, OR at least one stage improvement in liver fibrosis and no worsening of steatohepatitis).

Not covered when

  • Cirrhosis (stage F4) — patient must have noncirrhotic MASH; progression to F4 results in discontinuation at renewal
  • Concomitant use with other GLP-1 agonist agents

Policy note: For patients with both T2DM and MASH, Wegovy may be approved for MASH but diabetes management must be handled by a separate GLP-1 agonist approved for that indication (per WV Preferred Drug List). The MASH indication does not exclude diabetic patients. Liver biopsy confirmation requires NAFLD activity score >= 4 with scores > 1 in all three components (steatosis, ballooning, lobular inflammation). Biopsy lookback is 1 year (12 months). No explicit imaging lookback stated for FibroScan/MRE. Continuation at 12 months requires no progression to cirrhosis and documented positive clinical response. Initial approval is 90 days; continuation approvals are 12 months.

Policy effective January 1, 2026 · verified June 3, 2026 · source: download

Why Wegovy requests get denied by West Virginia Medicaid

Based on what this policy asks for. Fix these before the first submission.

  1. Your plan's benefit excludes weight loss medications. A prior authorization cannot override a benefit exclusion — ask about a formulary exception or a different covered pathway.
  2. Wrong brand for the diagnosis. Wegovy and Ozempic are the same molecule with different approved uses; a request for Wegovy under a diagnosis that matches Ozempic is routinely denied.
  3. BMI not documented in the chart notes (or documented without a baseline weight and date).
  4. No documented diet and exercise program.
  5. Prescriber isn't the specialist the plan requires.

If weight loss isn't covered on your plan

West Virginia Medicaid has separate Wegovy policies that don't depend on the weight loss benefit:

Wegovy is also sold directly by Novo Nordisk without insurance through NovoCare.

Frequently asked questions

Does West Virginia Medicaid cover Wegovy?
West Virginia Medicaid does not cover it for weight loss on Medicaid.
How long does a Wegovy approval last with West Virginia Medicaid?
Initial approvals last 3 months, and renewals are granted in 6-month periods.
What does West Virginia Medicaid require to renew Wegovy?
Patient continues to meet all initial approval criteria AND demonstrates continued documented compliance AND is taking an appropriate maintenance dose of 1.7 mg or 2.4 mg per week. If 1.7 mg dose is intolerable, medication should be discontinued. Initial approval criteria (including T2DM/T1DM exclusion and A1C <= 6.5%) are re-verified at continuation and staying on a maintenance dose of at least 1.7 mg.
What if my plan excludes weight loss medications?
West Virginia Medicaid has separate Wegovy policies for heart disease risk reduction and liver disease (mash), which are covered on some plan types and don't depend on the weight-loss benefit. Wegovy is also available for cash through NovoCare.
How current is this information?
This page reflects West Virginia Medicaid's written policy as of January 1, 2026, last verified against the source document on June 3, 2026.

Other medications under West Virginia Medicaid

Wegovy coverage under other plans

All insurance plans · All medications

This page summarizes West Virginia Medicaid's written prior-authorization policy. It is not a guarantee of coverage; plans vary by employer and benefit design. Verify with your plan before relying on it.